GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

Sunday, December 25, 2016

FDA Perspective on Risk Management and its Influence on Quality

Image result for fdaIn the framework of a conference on Quality and Manufacturing, David J. Jaworski, Senior Policy Advisor of CDER's Office of Manufacturing and Product Quality gave a presentation on risk management and its influence on quality. The slides of his presentation are now freely available.
The presentation starts quoting Theodore Roosevelt: "Risk is like fire: If controlled it will help you; if uncontrolled it will rise up and destroy you" - and Trevor Levine: "Risk Management is about people and processes and not about models and technology."
Then, he carried on stating the most frequent inspection deficiencies in 2015:
  • 21 CFR 211.22(d): Quality Unit responsibilities
  • 21 CFR 211.160(b): Laboratory controls
  • 21 CFR 211.192: Investigation failures
  • 21 CFR 211.113(b): Microbiological controls
  • 21 CFR 211.100(a): Production process
  • 21 CFR 211.42(c)(19(iv): Environmental monitoring
  • 21 CFR 211.68(a): Electronic equipment controls  
Under the title "Risk Reduction is Hard Work", he gave three examples:
The first example deals with tablet blend uniformity which has been improved by replacing direct pressing through wet granulation. Besides, the process had been continuously operated and assisted by Process Analytical Technologies (PAT) applications.
The second example concentrates on sterile production focussed on microbiological risks and human intervention. For Jaworski, the difference between a classical cleanroom and a Restricted Access Barrier Systems (RABS) is that - through human intervention in the laminar flow - classical cleanrooms are subject to higher risks than RABS. According to him, completely encapsulated systems present the lowest risks.
Finally, the third example on manufacturing documentation shows how electronic systems - provided they are well designed - can help reducing risks and errors. For Jaworski, it is a general problem that SOPs and batch documentation are often written in a not very user-friendly way by the scientists. Partially, employees even require SOPs to be able to fulfil batch documents at all. Yet, even if the paper document is well designed, the risk of erroneous entries still remains. According to Jaworski, the change to an electronic system doesn't always reduce the risk of erroneous entries because when badly designed batch documentation is duplicated into an electronic version, the document is and remains a badly designed document with the same risks of errors. For Jaworski, an electronic system which ideally leads the employee through the entire manufacturing process and only requires a few manual entries could help strongly minimising risks.
In a perfect world, such a system would also perform error checks.
For more detailed information please also see the slides of the presentation entitled "Managing Risk to Quality: The Good and the Bad" (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images posted here are belongs to respective to Authority / owners of firm.


Post a Comment

Related Posts Plugin for WordPress, Blogger...


Popular Posts


Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner



Subscribe via email for free


Enter your email address:

Delivered by FeedBurner

Contact Form


Email *

Message *

Menu :
Powered by Blogger.



    Related Posts Plugin for WordPress, Blogger...


    2016 (37) 2017 (85) 2018 (9) 211 CFR (1) 211.63 (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (70) FDA Guide (18) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (39) MAR17 (13) Mar18 (7) May17 (10) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (43) WHO (6) zika (1)


    Theme Support